Mental Health

A new app, born from its founder's personal health battle, challenges the 'no pain, no gain' ethos of digital wellness with a flexible, empathetic model.

Replacing a controversial task force, Canada's new NACPHS aims to modernize health guidelines with a focus on equity, patient input, and scientific agility.

An insurer's multi-million-dollar investment in anxiety care, featuring animal therapy, signals a shift in corporate responsibility. But what does it mean?

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

As illicit tobacco and vapes flood India, Big Tobacco calls for a crackdown. But is this a genuine partnership or a strategic play in a global shadow economy?

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

Arlow's new platform moves beyond reactive crisis management, using a hybrid AI and human-led system to proactively manage the entire aging journey.

Ottawa unveils the Safe Social Media Act, proposing an under-16 ban and a new regulator. Will this bold move save kids or stifle innovation?

Beyond the fireworks and festivities, Canada Day 2026 reveals a sophisticated strategy of public-private partnership and multi-platform engagement.

A new survey reveals a major disconnect between American values on volunteerism and corporate action, posing a hidden risk to talent retention and ESG ratings.

A new grand jury report exposes a perfect storm in SF jails: surging inmates with severe health needs, crumbling buildings, and burned-out staff.

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

A $95K grant fuels an innovative Chicago partnership integrating community doulas into hospitals, aiming to reverse the deadly trend of Black maternal mortality.